Lu-177-Labeled Zirconia Particles for Radiation Synovectomy

Andras Polyak, Lívia Naszályi Nagy, Eszter Drotár, Gabriella Dabasi, Róbert P. Jóba, Zita Pöstényi, Renata Mikolajczak, A. Bóta, L. Balogh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The present article describes the preparation of β-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new 177Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed radiopharmaceutical compound were observed through a scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 μm mean diameter and showed high in vitro radiochemical and colloid size stability at room temperature and during the blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with single-photon emission computed tomography (SPECT) imaging follow-up measurements and a dual-isotope SPECT imaging tests with conventional 99mTc-methanediphosphonic acid bone scintigraphy. In the treated dog, no clinical side-effects or signs of histopathological changes of the joints were recorded during the treatment. SPECT follow-up studies clearly and conspicuously showed the localization of the 177Lu-labeled colloid in the hock joint as well as detectable but negligible leakages of the radiocolloid in the nearest lymph node. On the basis of biological follow-up tests, the orthopedic team assumed that the 177Lu-labeled zirconia colloid-based local radionuclide therapy resulted in a significant and long-term improvement in clinical signs of the patient without any remarkable side-effects.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume30
Issue number10
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Colloids
Radiation
Animal Tarsus
Single-Photon Emission-Computed Tomography
Radiopharmaceuticals
Joints
Radioisotopes
Lutetium
Dog Diseases
Therapeutics
Isotopes
Radionuclide Imaging
Nanoparticles
Orthopedics
Lymph Nodes
zirconium oxide
Dogs
Electrons
Bone and Bones
Temperature

Keywords

  • 177Lu
  • Local radiotherapy
  • Radionuclide therapy
  • Radiosynovectomy
  • Rheumatoid arthritis
  • Zirconia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Polyak, A., Nagy, L. N., Drotár, E., Dabasi, G., Jóba, R. P., Pöstényi, Z., ... Balogh, L. (2015). Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. Cancer Biotherapy and Radiopharmaceuticals, 30(10), 433-438. https://doi.org/10.1089/cbr.2015.1881

Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. / Polyak, Andras; Nagy, Lívia Naszályi; Drotár, Eszter; Dabasi, Gabriella; Jóba, Róbert P.; Pöstényi, Zita; Mikolajczak, Renata; Bóta, A.; Balogh, L.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 30, No. 10, 01.12.2015, p. 433-438.

Research output: Contribution to journalArticle

Polyak, A, Nagy, LN, Drotár, E, Dabasi, G, Jóba, RP, Pöstényi, Z, Mikolajczak, R, Bóta, A & Balogh, L 2015, 'Lu-177-Labeled Zirconia Particles for Radiation Synovectomy', Cancer Biotherapy and Radiopharmaceuticals, vol. 30, no. 10, pp. 433-438. https://doi.org/10.1089/cbr.2015.1881
Polyak A, Nagy LN, Drotár E, Dabasi G, Jóba RP, Pöstényi Z et al. Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. Cancer Biotherapy and Radiopharmaceuticals. 2015 Dec 1;30(10):433-438. https://doi.org/10.1089/cbr.2015.1881
Polyak, Andras ; Nagy, Lívia Naszályi ; Drotár, Eszter ; Dabasi, Gabriella ; Jóba, Róbert P. ; Pöstényi, Zita ; Mikolajczak, Renata ; Bóta, A. ; Balogh, L. / Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. In: Cancer Biotherapy and Radiopharmaceuticals. 2015 ; Vol. 30, No. 10. pp. 433-438.
@article{71bf8e99052b4727a6250262702ed895,
title = "Lu-177-Labeled Zirconia Particles for Radiation Synovectomy",
abstract = "The present article describes the preparation of β-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new 177Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed radiopharmaceutical compound were observed through a scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 μm mean diameter and showed high in vitro radiochemical and colloid size stability at room temperature and during the blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with single-photon emission computed tomography (SPECT) imaging follow-up measurements and a dual-isotope SPECT imaging tests with conventional 99mTc-methanediphosphonic acid bone scintigraphy. In the treated dog, no clinical side-effects or signs of histopathological changes of the joints were recorded during the treatment. SPECT follow-up studies clearly and conspicuously showed the localization of the 177Lu-labeled colloid in the hock joint as well as detectable but negligible leakages of the radiocolloid in the nearest lymph node. On the basis of biological follow-up tests, the orthopedic team assumed that the 177Lu-labeled zirconia colloid-based local radionuclide therapy resulted in a significant and long-term improvement in clinical signs of the patient without any remarkable side-effects.",
keywords = "177Lu, Local radiotherapy, Radionuclide therapy, Radiosynovectomy, Rheumatoid arthritis, Zirconia",
author = "Andras Polyak and Nagy, {L{\'i}via Nasz{\'a}lyi} and Eszter Drot{\'a}r and Gabriella Dabasi and J{\'o}ba, {R{\'o}bert P.} and Zita P{\"o}st{\'e}nyi and Renata Mikolajczak and A. B{\'o}ta and L. Balogh",
year = "2015",
month = "12",
day = "1",
doi = "10.1089/cbr.2015.1881",
language = "English",
volume = "30",
pages = "433--438",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Lu-177-Labeled Zirconia Particles for Radiation Synovectomy

AU - Polyak, Andras

AU - Nagy, Lívia Naszályi

AU - Drotár, Eszter

AU - Dabasi, Gabriella

AU - Jóba, Róbert P.

AU - Pöstényi, Zita

AU - Mikolajczak, Renata

AU - Bóta, A.

AU - Balogh, L.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The present article describes the preparation of β-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new 177Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed radiopharmaceutical compound were observed through a scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 μm mean diameter and showed high in vitro radiochemical and colloid size stability at room temperature and during the blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with single-photon emission computed tomography (SPECT) imaging follow-up measurements and a dual-isotope SPECT imaging tests with conventional 99mTc-methanediphosphonic acid bone scintigraphy. In the treated dog, no clinical side-effects or signs of histopathological changes of the joints were recorded during the treatment. SPECT follow-up studies clearly and conspicuously showed the localization of the 177Lu-labeled colloid in the hock joint as well as detectable but negligible leakages of the radiocolloid in the nearest lymph node. On the basis of biological follow-up tests, the orthopedic team assumed that the 177Lu-labeled zirconia colloid-based local radionuclide therapy resulted in a significant and long-term improvement in clinical signs of the patient without any remarkable side-effects.

AB - The present article describes the preparation of β-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new 177Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed radiopharmaceutical compound were observed through a scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 μm mean diameter and showed high in vitro radiochemical and colloid size stability at room temperature and during the blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with single-photon emission computed tomography (SPECT) imaging follow-up measurements and a dual-isotope SPECT imaging tests with conventional 99mTc-methanediphosphonic acid bone scintigraphy. In the treated dog, no clinical side-effects or signs of histopathological changes of the joints were recorded during the treatment. SPECT follow-up studies clearly and conspicuously showed the localization of the 177Lu-labeled colloid in the hock joint as well as detectable but negligible leakages of the radiocolloid in the nearest lymph node. On the basis of biological follow-up tests, the orthopedic team assumed that the 177Lu-labeled zirconia colloid-based local radionuclide therapy resulted in a significant and long-term improvement in clinical signs of the patient without any remarkable side-effects.

KW - 177Lu

KW - Local radiotherapy

KW - Radionuclide therapy

KW - Radiosynovectomy

KW - Rheumatoid arthritis

KW - Zirconia

UR - http://www.scopus.com/inward/record.url?scp=84951293484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951293484&partnerID=8YFLogxK

U2 - 10.1089/cbr.2015.1881

DO - 10.1089/cbr.2015.1881

M3 - Article

VL - 30

SP - 433

EP - 438

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 10

ER -